Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

about

The human cytomegalovirus terminase complex as an antiviral target: a close-up view.Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation

P2860

Q47549828-F8753E83-08A6-4078-BE75-A15138088100 Q57053200-1455CE0D-F2B3-4F24-AF26-190A5779CA96

P2860

Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

Item

http://www.wikidata.org/entity/Q40272806

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacokinetics and safety of ...... atients with renal impairment.

@en

type

Item

label

Pharmacokinetics and safety of ...... atients with renal impairment.

@en

prefLabel

Pharmacokinetics and safety of ...... atients with renal impairment.

@en

P1476

Pharmacokinetics and safety of ...... atients with renal impairment.

@en

P2093

Arne van Schanke

http://www.w3.org/2001/XMLSchema#string

Atef Halabi

http://www.w3.org/2001/XMLSchema#string

Dirk Kropeit

http://www.w3.org/2001/XMLSchema#string

Ellen G J Hulskotte

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Stobernack

http://www.w3.org/2001/XMLSchema#string

Helga Rübsamen-Schaeff

http://www.w3.org/2001/XMLSchema#string

Holger Zimmermann

http://www.w3.org/2001/XMLSchema#string

Jürgen Scheuenpflug

http://www.w3.org/2001/XMLSchema#string

Katharina Erb-Zohar

http://www.w3.org/2001/XMLSchema#string

P2860

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.

Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.

Hepatic drug clearance: the effect of age using indocyanine green as a model compound

The effect of renal failure on hepatic drug clearance.

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.

Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection.

Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

Consequences of renal failure on non-renal clearance of drugs.

P304

1944-1953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13292

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28345163

http://www.w3.org/2001/XMLSchema#string

P932

5555856

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

about

P2860

P2860

Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932